Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Treasury Shares: 2023-2024

  • Corvus Pharmaceuticals' Treasury Shares was N/A to $400,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $400,000, marking a year-over-year change of. This contributed to the annual value of $400,000 for FY2023, which is N/A change from last year.
  • According to the latest figures from Q3 2024, Corvus Pharmaceuticals' Treasury Shares is $400,000, which was down 0.00% from $400,000 recorded in Q2 2024.
  • Corvus Pharmaceuticals' Treasury Shares' 5-year high stood at $400,000 during Q4 2023, with a 5-year trough of $400,000 in Q4 2023.
  • Moreover, its 2-year median value for Treasury Shares was $400,000 (2024), whereas its average is $400,000.